Date | Title | Description | |
---|---|---|---|
22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
03 Nov 2021 | On buy-back programmes | The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. | Download |
16 Jul 2021 | On Corporate Governance | ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company | Download |
22 Jun 2021 | On significant placements in financial instruments | Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
09 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 2 February and 8 February 2024 | Download |
02 Feb 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 26 January and 1 February 2024 | Download |
26 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 19 January and 25 January 2024 | Download |
19 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 12 January and 18 January 2024 | Download |
12 Jan 2024 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted between 5 January and 11 January 2024 | Download |
Pages
Date | Title | Description | |
---|---|---|---|
06 Apr 2017 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the first quarter of 2017 | Download |
13 Mar 2017 | Otros sobre negocio y situación financiera | The Company releases the presentation related to its biosimilar of Enoxaparin | Download |
07 Mar 2017 | Otros sobre negocio y situación financiera | ROVI informs that the Decentralised procedure used for the registration of its biosimilar of enoxaparin has been completed with positive outcome | Download |
16 Feb 2017 | Otros sobre Gobierno Corporativo | The Company informs about the agreements adopted by the Board of Directors | Download |
16 Feb 2017 | Informe anual de remuneraciones de los consejeros | ROVI releases the 2016 annual report regarding remuneration of the members of the Board of Directors | Download |